3 Sep 2015 09:34
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Change of Registered Office & Trading Address
Advanced Oncotherapy plc has changed its registered office address to:
Level 17, Dashwood House, 69 Old Broad Street, London EC2M 1QS.
And its trading and correspondence address to:
Third Floor, Clearwater House, 4-7 Manchester Street, London W1U 3AE
Advanced Oncotherapy Plc | www.avoplc.com |
Sanjeev Pandya, CEO | Tel: +44 20 3617 8728 |
Nicolas Serandour, CFO |
|
|
|
Westhouse Securities (Nomad & Joint Broker) |
|
Antonio Bossi / David Coaten | Tel: +44 20 7601 6100 |
|
|
Beaufort Securities (Joint Broker) |
|
Jon Levinson / Zoe Alexander | Tel: +44 20 7382 8300 |
|
|
Walbrook PR (Financial PR & IR) | Tel: +44 20 7933 8780 or avo@walbrookpr.com |
Paul McManus / Anna Dunphy | Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy's team "ADAM" based in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.
Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.
The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.